NCT04233372

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 399 (actual)
• Sponsor: Hospital Clinic of Barcelona · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.

Conditions

• Hiv

Interventions

Type	Name	Description
DRUG	Delstrigo	Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil. 1 covered tablet for day .( will be administered 28 days maximum)

Timeline

• Start date: 2020-08-27
• Primary completion: 2022-07-28
• Completion: 2022-07-28
• First posted: 2020-01-18
• Last updated: 2025-09-10
• Results posted: 2025-09-10

Locations

2 sites across 2 countries: France, Spain